At a glance
ClinicalIndex Comparison RecordN/ACompleted· 51 enrolled
Drug / intervention
Renal Denervation (Vessix) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE
In Brief
A clinical study evaluating Renal Denervation (Vessix) and Renal Angiography for Hypertension. Completed, enrolled 51 participants across 12 sites.
Detailed Summary
The REDUCE HTN: REINFORCE study is being conducted to determine whether the Vessix Reduce™ Catheter and Vessix™ Generator for the treatment of uncontrolled hypertension (off-treatment office systolic blood pressure ≥150 mmHg and ≤180 mmHg) shows acceptable performance at 8 weeks when compared to a masked procedure (renal angiogram).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionSep 2017
Study CompletionAug 2019
TodayJul 2026
First PostedMar 19, 2015
Enrollment StartApr 1, 2015
Primary CompletionSep 7, 2017
Study CompletionAug 2, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.3 years ago
Interventions
Renal Denervation (Vessix)device
Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
Renal Angiographydevice
Percutaneous renal angiography